Navigation Links
CareFusion Announces 510(k) Clearance and U.S. Launch of New Advanced Electrodiagnostic System
Date:3/20/2012

SAN DIEGO, March 20, 2012 /PRNewswire/ -- CareFusion announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new electrodiagnostic system, known as the Viking on Nicolet® EDX. The EDX system is a multi-modality device for monitoring and testing electrophysiological information from the human nervous and muscular system.

(Logo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)

The new EDX system offers an intuitive, ergonomic platform and clinical automation that enables efficient, high-quality nerve conduction studies (NCS), electromyography (EMG) and evoked potential (EP) testing and intra-operative monitoring (IOM). The strong signal quality, environmental noise suppression capability and artifact rejection feature help reduce examination time, which can enhance patient comfort. 

Designed with input from neurologists and electrodiagnostic technicians, the EDX system also helps improve workflow in busy clinical settings by effectively organizing data into a variety of reporting formats. With the versatile system, clinicians can complete their studies and generate reports with ease, helping to streamline workflow, improve clinician efficiency and lower costs.

"We are excited to bring the Viking on Nicolet EDX system to the U.S. market," said Mary de Sousa, vice president and general manager of the Nicolet business of CareFusion. "The EDX system helps strengthen our market-leading EMG portfolio and ensures clinicians and patients can benefit from the latest advancements in neurological care."

The EDX system will now be available in the United States and many other countries worldwide. The product will also be featured at the
'/>"/>

SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. CareFusion Reports First Quarter Fiscal 2012 Results
2. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
3. GeoVax Announces Private Placement of $2.2 Million
4. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
5. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
6. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
7. Floridas Leading Fertility Center Announces Successful Baby Delivery via Egg Freezing
8. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
9. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
10. Proteonomix Announces a Private Placement of $3.8 Million
11. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Arbor, Mich. Every day, their baby stopped breathing, ... to his lungs. April and Bryan Gionfriddo watched helplessly, ... , "Quite a few doctors said he had a ... April Gionfriddo, about her now 20-month-old son, Kaiba. "At ... we would take it and run with it." , ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... present at the Jefferies 2013 Global Healthcare Conference to ... New York. Richard Smith ... Hai Tran , Chief Financial Officer, will present ... Daylight Time.   About BioScrip BioScrip, ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Graphite ... self-lubricating bushings mounted in stainless steel pillow ... properties of GRAPHALLOY with the application and installation ... Steel Pillow Blocks work exceptionally well when ... or hostile liquids such as acids, alkalies, hydrocarbons, ...
(Date:5/23/2013)... 2013 PuraMed BioScience ® , Inc., ... over-the-counter (OTC) medicinal and healthcare products, announced that ... company based on low market capitalization valuation. ... Natural Product to Treat Migraine Headaches , ... Competitor , Currently Available Nationwide at Walgreen,s ...
Breaking Biology Technology:Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3
... , , ... that it has entered into a cooperative research and development ... (NIAID), part of the National Institutes of Health (NIH), to ... mycobacteria (NTM) lung infections. , , Transave ...
... BEIJING, July 30 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, ... a growing developer and,producer of prescriptions drugs and ... Republic of China, today reported it received notice,of ... of the People,s,Republic of China for its innovative ...
... Dendreon Corporation (Nasdaq: DNDN ) management will host a conference call on ... quarter 2009 financial results. Access to the discussion may be obtained as follows: ... 11:30 AM ET /8:30 AM PT, Date: ... or +1-719-325-4873 (international), Webcast: www.dendreon.com (homepage and investor relations ...
Cached Biology Technology:Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria 2Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria 3Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria 4Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets 2Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets 3Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET 2
(Date:5/23/2013)... year, carrying more than 284 million tons of cargo, transit ... in toll fees for the Panama Canal Authority. Each time ... water are used from Gatun Lake, which is also a ... the isthmus. , However, the advent of very large ... ships at sea, has demanded change. The Panama Canal is ...
(Date:5/23/2013)... which estrogen suppresses lipid synthesis in the liver, UC ... treating certain liver diseases. , With this finding, ... long-held views in the field. Study results appear in ... Signaling . , "The dogma in the steroid receptor ... located in the nucleus respond to steroid hormones by ...
(Date:5/23/2013)... overall health, development, and academic success of children, ... that all students have opportunities to engage in ... or moderate-intensity physical activity, says a new report ... suggest that only about half of school-age children ... and development. The report recommends that most ...
Breaking Biology News(10 mins):Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3
... eyes are closed, the visual centers in our brain are ... in the last few years that the magnitude of sense-related ... is quite similar to that of one exposed to a ... of that activity, explaining why, even though our sense centers ...
... ESA is now gearing up to return to Russia to ... now envisaged for launch on 16 March 2009. This follows ... Rockot launcher that delayed the launch of GOCE by Eurockot ... has just arrived at the Plesetsk Cosmodrome in northern Russia ...
... at Albert Einstein College of Medicine of Yeshiva University have ... and causes disease. The study, published in ... ( PNAS ), may help scientists develop new therapies ... These fungal infections occur most commonly in those with compromised ...
Cached Biology News:Behind closed eyes 2March launch planned for ESA's gravity mission 2Scientists discover how deadly fungus protects itself 2
... A very potent Rnase free ... over a broad range of ... protein does not inhibit SP6, ... AMV and M-MLV reverse transcriptase ...
... kit, 110 to 220 V, enables ... doubles flow rates and valve capacity ... kit includes the Maximizer base unit, ... tubing kit, system cable 30, and ...
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
Mouse polyclonal antibody to QDPR - quinoid dihydropteridine reductase...
Biology Products: